or Try an Advanced Search...

    Technical Analysis for ALT - Altimmune, Inc.

    Grade Last Price % Change Price Change
    F 6.75 0.90% 0.06
    ALT closed up 0.9 percent on Friday, July 26, 2024, on 59 percent of normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    Earnings due: Aug 8
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ALT trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    50 DMA Resistance Bearish 0.00%
    Shooting Star Candlestick Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 0.90%
    Oversold Stochastic Weakness 0.90%
    180 Bearish Setup Bearish Swing Setup 7.66%
    Stochastic Buy Signal Bullish 7.66%
    NR7 Range Contraction 7.66%
    Older End-of-Day Signals for ALT ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 12 hours ago
    20 DMA Resistance about 13 hours ago
    50 DMA Resistance about 13 hours ago
    Rose Above 20 DMA about 13 hours ago
    Rose Above 50 DMA about 13 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ALT Chart by TradingView
    Basic chart:

    Profile

    Altimmune, Inc. Description

    Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Phosphates Manufacturing Process Obesity Vaccines Reversal Nerve Manufacturing Processes Biodefense Choline Biological Warfare Anthrax Chemical Warfare Cholinesterase Anthrax Vaccines Athene

    Is ALT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 25 Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
    Jul 2 Altimmune to Participate at Leerink Partners Therapeutics Forum
    Jun 26 Altimmune CFO Richard Eisenstadt passes away
    Jun 26 Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
    Jun 24 Crypto under pressure, Good Buy or Goodbye: Market Domination
    Jun 24 Altimmune reports positive results in weight-loss drug trial
    Jun 24 Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
    Jun 24 Biggest stock movers today: Crypto stocks, AFRM, ALNY, and more
    Jun 24 Altimmune jumps 13% on phase 2 pemvidutide results for obesity
    Jun 23 Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
    See more ALT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.84
    52 Week Low 2.09
    Average Volume 3,683,666
    200-Day Moving Average 7.33
    50-Day Moving Average 7.01
    20-Day Moving Average 6.97
    10-Day Moving Average 6.88
    Average True Range 0.57
    RSI (14) 48.19
    ADX 14.82
    +DI 27.63
    -DI 22.66
    Chandelier Exit (Long, 3 ATRs) 6.56
    Chandelier Exit (Short, 3 ATRs) 7.76
    Upper Bollinger Bands 8.11
    Lower Bollinger Band 5.84
    Percent B (%b) 0.4
    BandWidth 32.55
    MACD Line -0.09
    MACD Signal Line -0.02
    MACD Histogram -0.0721
    Fundamentals Value
    Market Cap 362.67 Million
    Num Shares 53.7 Million
    EPS -1.54
    Price-to-Earnings (P/E) Ratio -4.38
    Price-to-Sales 1976.80
    Price-to-Book 3.74
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.37
    Resistance 3 (R3) 7.43 7.28 7.26
    Resistance 2 (R2) 7.28 7.13 7.25 7.23
    Resistance 1 (R1) 7.02 7.03 6.95 6.96 7.19
    Pivot Point 6.87 6.87 6.84 6.84 6.87
    Support 1 (S1) 6.61 6.72 6.54 6.55 6.31
    Support 2 (S2) 6.46 6.62 6.43 6.27
    Support 3 (S3) 6.20 6.46 6.24
    Support 4 (S4) 6.14